Dyne Therapeutics Announces “Breakthrough Article”

Published program data shows Dyne’s FORCE™ platform achieves enhanced exon skipping and prolonged dystrophin restoration in Duchenne in vivo mdx mouse model

CureDuchenne provided funding to Dyne Therapeutics and we are very pleased to see their positive preclinical data showing significant dystrophin restoration in muscle, including the diaphragm and heart, in mdx mice. We’re looking forward to the initiation of their Duchenne clinical trial later this year, likely for people living with Duchenne who are amenable to exon 51 skipping. Exons 53, 45 and 44 are also likely future targets.